John Overdeck’s Achieve Life Sciences ACHV Stock Holding History

John Overdeck’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88M	Sell	441,187 -147,364	-25%	-$703K	﹤0.01%	2661
2026 Q1	$1.73M	Sell	588,551 -160,065	-21%	-$711K	﹤0.01%	2865
2025 Q4	$3.72M	Buy	748,616 +309,552	+71%	+$1.35M	0.01%	1956
2025 Q3	$1.38M	Buy	+439,064	New	+$1.21M	﹤0.01%	2370
2021 Q4	–	Sell	-18,532	Closed	-$158K	–	4193
2021 Q3	$158K	Sell	18,532 -25,887	-58%	-$203K	﹤0.01%	4015
2021 Q2	$399K	Buy	+44,419	New	+$423K	﹤0.01%	3286
2015 Q2	–	Sell	-11	Closed	-$52K	–	2757
2015 Q1	$52K	Sell	11 -39	-78%	-$192K	﹤0.01%	2580
2014 Q4	$251K	Buy	+50	New	+$244K	﹤0.01%	1979
2014 Q3	–	Sell	-9	Closed	-$74K	–	1712
2014 Q2	$74K	Buy	+9	New	+$111K	﹤0.01%	2069
2014 Q1	–	Sell	-10	Closed	-$181K	–	1949
2013 Q4	$181K	Buy	+10	New	+$175K	﹤0.01%	2029

Other funds holding ACHV

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

John Overdeck's ACHV Position: Q2 2026 in Review

John Overdeck reduced its Achieve Life Sciences (ACHV) stake by 25% in Q2 2026, selling an estimated $703K and leaving 441,187 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

John Overdeck first reported a position in ACHV in Q4 2013 and has held it in 10 quarters since. The position peaked at $3.72M in Q4 2025. 110 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

John Overdeck held 441,187 shares of Achieve Life Sciences worth $2.88M as of Q2 2026.
John Overdeck sold 147,364 Achieve Life Sciences shares in Q2 2026, an estimated $703K.
Achieve Life Sciences made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2661 holding.
John Overdeck first reported a position in Achieve Life Sciences in Q4 2013 and has held it in 10 quarters since.
John Overdeck's Achieve Life Sciences position peaked at $3.72M in Q4 2025.
110 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.